LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test

/PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of...

Related Keywords

United Kingdom ,London ,City Of ,Ron Zwanziger ,Exchange Commission ,Fast Lab Solutions ,Lumiradx Fast Lab Solutions ,Lumiradx Point ,Lab Solutions ,Lumiradx Chairman ,Care Platform ,Fast Lab ,Emergency Use Authorization ,Lumiradx Platform ,Securities Litigation Reform Act ,Proxy Statement ,Lumiradx ,